Journal of Clinical Oncology, Vol 2, 1390-1396, Copyright © 1984 by American Society of Clinical Oncology
Randomized study of systemic chemotherapy following complete excision of nonosseous sarcomas
JH Edmonson, TR Fleming, JC Ivins, EO Burgert Jr, EH Soule, MJ O'Connell, FH Sim and DL Ahmann
Between June 1975 and April 1981, 61 of the 177 eligible patients whose
nonosseous sarcomas of extremity or trunk origin had been completely
excised primarily or after local recurrences agreed to participate in a
randomized study of adjuvant chemotherapy. Dermatofibrosarcoma, lymphomas,
myeloma, Kaposi's sarcoma, and embryonal rhabdomyosarcoma were excluded as
were patients with significant second primary cancers and those who
received either preoperative or postoperative radiation therapy. After
stratification by anatomic status of disease, site of origin, and
histologic grade, a random one half of the 61 participants began
alternating courses of vincristine/cyclophosphamide/dactinomycin, and
vincristine/doxorubicin/dacarbazine at six-week intervals for one year. The
control group was evaluated at six-week intervals without adjuvant
chemotherapy, but these patients were offered this chemotherapy later if
they had progressive disease excised. Although 30% of the 61 patients
experienced local recurrence of disease within the first five years after
randomization, and only 54% were continuously disease free for five or more
years, 82% were surviving at five years (Kaplan-Meier calculations) with a
median follow-up of 64.3 months. Partial suppression of distant metastasis
by adjuvant chemotherapy was apparent in the overall study, in the
extremity tumor category, and in the subgroup of patients who had received
limb-sparing surgery; however, no survival advantage for
chemotherapy-treated patients was demonstrated. The 30 adjuvant
chemotherapy-treated patients received a total of three thoracotomies as
compared with 17 salvage thoracotomies for the 31 control patients;
however, salvage surgery for local recurrences has been similar in the two
groups. Recent improvement in the survival of patients with soft-tissue
sarcomas is not necessarily a result of adjuvant chemotherapy or radiation
therapy.